RU2014101070A - Ингибирующие глиобластому соединения и их применение - Google Patents
Ингибирующие глиобластому соединения и их применение Download PDFInfo
- Publication number
- RU2014101070A RU2014101070A RU2014101070/04A RU2014101070A RU2014101070A RU 2014101070 A RU2014101070 A RU 2014101070A RU 2014101070/04 A RU2014101070/04 A RU 2014101070/04A RU 2014101070 A RU2014101070 A RU 2014101070A RU 2014101070 A RU2014101070 A RU 2014101070A
- Authority
- RU
- Russia
- Prior art keywords
- glioblastoma
- changes
- gene encoding
- hydrogen
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/06—Peri-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161497215P | 2011-06-15 | 2011-06-15 | |
| US61/497,215 | 2011-06-15 | ||
| PCT/EP2012/061485 WO2012172069A1 (en) | 2011-06-15 | 2012-06-15 | Glioblastoma inhibiting compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014101070A true RU2014101070A (ru) | 2015-07-20 |
Family
ID=46319762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014101070/04A RU2014101070A (ru) | 2011-06-15 | 2012-06-15 | Ингибирующие глиобластому соединения и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9573960B2 (enExample) |
| EP (1) | EP2721035B1 (enExample) |
| JP (1) | JP6228113B2 (enExample) |
| CN (1) | CN103764659A (enExample) |
| AU (1) | AU2012268984B2 (enExample) |
| BR (1) | BR112013032360A2 (enExample) |
| CA (1) | CA2838945A1 (enExample) |
| CL (1) | CL2013003563A1 (enExample) |
| IL (1) | IL229767A0 (enExample) |
| MX (1) | MX340816B (enExample) |
| PH (1) | PH12013502530A1 (enExample) |
| RU (1) | RU2014101070A (enExample) |
| WO (1) | WO2012172069A1 (enExample) |
| ZA (1) | ZA201309365B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014023329A1 (en) | 2012-08-06 | 2014-02-13 | Life And Brain Gmbh | Niclosamide and its derivatives for use in the treatment of solid tumors |
| WO2016210289A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
| EP3328495A4 (en) * | 2015-07-31 | 2019-01-16 | Swedish Health Services | METHOD AND COMPOSITIONS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS |
| WO2017048800A1 (en) * | 2015-09-15 | 2017-03-23 | Swedish Health Services | Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof |
| CN105802928A (zh) * | 2016-03-30 | 2016-07-27 | 苏州偲聚生物材料有限公司 | 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒 |
| CN105796549A (zh) * | 2016-04-22 | 2016-07-27 | 中国医学科学院基础医学研究所 | 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途 |
| CN107475213A (zh) * | 2016-06-08 | 2017-12-15 | 中国科学院苏州纳米技术与纳米仿生研究所 | 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒 |
| WO2019178059A1 (en) | 2018-03-13 | 2019-09-19 | Georgetown University | ENHANCING CHEMOTHERAPY IN MEDULLOBLASTOMA AND GLIOBLASTOMA WITH HIGH BASAL p53 LEVELS |
| CN110433154A (zh) * | 2019-08-12 | 2019-11-12 | 昆明理工大学 | 藤黄酸的新用途 |
| WO2023183463A1 (en) * | 2022-03-23 | 2023-09-28 | University Of Cincinnati | Methods of potentiating temozolomide activity against glioblastoma cells |
| CN117538458B (zh) * | 2024-01-09 | 2024-03-29 | 中国医学科学院北京协和医院 | 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000045165A1 (en) * | 1999-02-01 | 2000-08-03 | Cytovia, Inc. | Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products |
| US6462041B1 (en) * | 1999-05-21 | 2002-10-08 | Cytovia, Inc. | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis |
| JP3904364B2 (ja) | 2000-03-03 | 2007-04-11 | 独立行政法人科学技術振興機構 | 抗マラリア活性を有する新規化合物 |
| EP1300403A1 (en) | 2001-10-02 | 2003-04-09 | Aventis Pharma S.A. | Process for the manufacture of hypoxyxylerone derivatives |
| WO2008148008A1 (en) * | 2007-05-23 | 2008-12-04 | Emory University | High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity |
| CN101289482B (zh) * | 2007-09-29 | 2011-08-31 | 辽宁利锋科技开发有限公司 | 藤黄酸苷衍生物和类似物及其制备方法和用途 |
| PA8851101A1 (es) * | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
-
2012
- 2012-06-15 JP JP2014515214A patent/JP6228113B2/ja not_active Expired - Fee Related
- 2012-06-15 BR BR112013032360A patent/BR112013032360A2/pt not_active IP Right Cessation
- 2012-06-15 EP EP12728260.6A patent/EP2721035B1/en not_active Not-in-force
- 2012-06-15 RU RU2014101070/04A patent/RU2014101070A/ru not_active Application Discontinuation
- 2012-06-15 AU AU2012268984A patent/AU2012268984B2/en not_active Expired - Fee Related
- 2012-06-15 US US14/126,512 patent/US9573960B2/en not_active Expired - Fee Related
- 2012-06-15 MX MX2013014708A patent/MX340816B/es active IP Right Grant
- 2012-06-15 CN CN201280028960.8A patent/CN103764659A/zh active Pending
- 2012-06-15 CA CA2838945A patent/CA2838945A1/en not_active Abandoned
- 2012-06-15 WO PCT/EP2012/061485 patent/WO2012172069A1/en not_active Ceased
- 2012-06-15 PH PH1/2013/502530A patent/PH12013502530A1/en unknown
-
2013
- 2013-12-02 IL IL229767A patent/IL229767A0/en unknown
- 2013-12-11 ZA ZA2013/09365A patent/ZA201309365B/en unknown
- 2013-12-12 CL CL2013003563A patent/CL2013003563A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2721035A1 (en) | 2014-04-23 |
| IL229767A0 (en) | 2014-01-30 |
| PH12013502530A1 (en) | 2014-01-27 |
| EP2721035B1 (en) | 2018-06-13 |
| US9573960B2 (en) | 2017-02-21 |
| CN103764659A (zh) | 2014-04-30 |
| WO2012172069A1 (en) | 2012-12-20 |
| CA2838945A1 (en) | 2012-12-20 |
| BR112013032360A2 (pt) | 2017-06-13 |
| NZ618170A (en) | 2015-04-24 |
| MX2013014708A (es) | 2014-08-18 |
| AU2012268984B2 (en) | 2016-07-14 |
| US20150148390A1 (en) | 2015-05-28 |
| JP2014517025A (ja) | 2014-07-17 |
| ZA201309365B (en) | 2015-11-25 |
| CL2013003563A1 (es) | 2014-06-06 |
| JP6228113B2 (ja) | 2017-11-08 |
| MX340816B (es) | 2016-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014101070A (ru) | Ингибирующие глиобластому соединения и их применение | |
| JP2014517025A5 (enExample) | ||
| Correia-Melo et al. | Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence? | |
| Dowling et al. | Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells | |
| Luo et al. | Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance | |
| Chang et al. | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase | |
| Huber et al. | NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression | |
| Van de Vosse et al. | Role of the nuclear envelope in genome organization and gene expression | |
| Albino et al. | The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment | |
| EA200401608A1 (ru) | Ингибиторы ассоциированной с иммунитетом протеинкиназы | |
| EP3421035A1 (en) | Novel use of chromone derivative as pharmaceutical composition for preventing and treating fibrosis by using epithelial-mesenchymal transition inhibitory activity thereof | |
| Bian et al. | Target deconvolution of a multikinase inhibitor with antimetastatic properties identifies TAOK3 as a key contributor to a cancer stem cell–like phenotype | |
| Barnes et al. | SIN3 is critical for stress resistance and modulates adult lifespan | |
| CN109562102A (zh) | 用于预防和/或治疗癌症的化合物、组合物和方法 | |
| CA2397681A1 (en) | Partially saturated calcium channel blockers | |
| Kechele et al. | Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation | |
| CN115917324A (zh) | 治疗癌症的方法 | |
| EP3615940B1 (en) | A method for determining myeloid natural killer (nk)-cells and use thereof | |
| CA3061703A1 (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| Lin et al. | Translationally controlled tumor protein promotes liver regeneration by activating mTORC2/AKT signaling | |
| Brandl et al. | Targeting c-MYC through Interference with NAMPT and SIRT1 and their association to oncogenic drivers in murine serrated intestinal tumorigenesis | |
| CA2963422A1 (en) | Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad | |
| CN109400545B (zh) | 一种精氨酸甲基转移酶5抑制剂及其应用 | |
| US20130295578A1 (en) | Methods for screening for drug resistance in cancer treatment | |
| Yan et al. | Discovery of tetrazolo-pyridazine-based small molecules as inhibitors of MACC1-driven cancer metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161107 |